Allergan Acquires Assets Of RetroSense For $60 Million Upfront Payment

Allergan plc has acquired almost all of the assets of RetroSense, a gene therapy company, for a $60 million upfront payment, the companies announced Tuesday. Allergan also agreed to pay regulatory and commercial milestone payments for the development of RetroSense's lead drug, RST-001, a gene therapy for the treament of Retinitis Pigmentosa.

Copyright © 2016 MarketWatch, Inc.